Once approved, Decapeptyl® 6-month formulation will be marketed by Debiopharm’s partners, such as Ipsen in most European Union countries. “This submission in Europe of our first 6-month-formulation ...
Ipsen (Euronext: FR0010259150; Paris: IPN) today announced the start of the filing process in Europe of the 6–month sustained release formulation of Decapeptyl ®, a luteinizing hormone releasing ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results